Abstract: The present disclosure relates to a device and a method for valuating a heat dissipation capability of a test platform of hydrogen fuel cell system. A plurality of PTC heaters are connected in series or in parallel in a primary or secondary dispersion water loop to simulate the fuel cell system with different heating powers. A rotation speed of water pump and whether a PTC is operated are controlled, thereby implementing steady and dynamic tests, and a test for integrative operating condition, thereby avoiding a real machine test from controlling a plurality of parameters. Compared with the real machine of a fuel cell, it can better test the heat dissipation capability of the fuel cell system. During the operation, the device does not need to be supplied reaction gases to ensure the safety of the test. The primary and secondary dispersion tests can be performed separately or in parallel.

Abstract: The present invention relates to various crystalline forms of (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide. The present invention also relates to pharmaceutical compositions comprising the crystalline forms.

Abstract: The present disclosure relates to a fuel cell technology, and in particular, to a method and a system for analyzing hydrogen refueling action of a fuel cell vehicle based on a big data platform. By extracting a structural design parameter set of a hydrogen system of a fuel cell vehicle and a driving data set of the fuel cell vehicle in a preset time period, and further analyzing the obtained hydrogen refueling action data, it calculates a first hydrogen refueling feature set and a second hydrogen refueling feature set of the fuel cell vehicle and finally obtain hydrogen refueling action features corresponding to driving of the fuel cell vehicle in a preset time period.

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: The present invention relates to processes for preparing 6-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (Compound I) in a large scale of over 1 Kg. The processes provide a good yield and a purity of at least 95% of the final product and provide a controllable and safe reaction.

Abstract: The present invention relates to an amorphous solid dispersion comprises 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (Compound I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer. The present invention also relates to pharmaceutical compositions comprising the amorphous solid dispersion. The amorphous solid dispersion of the present invention is stable upon storage and provides a better dissolution rate and bioavailability when comparing with a crystalline form.

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: The present invention relates to the field of golf hitting data analysis technology and discloses a golf hitting data analyzer, which includes a sensor group, a static golf ball detector, an ultra high speed motion detector, a cascaded high-speed motion target tracker, a hitting parameter calculator, and an output. In the present invention, the advanced image processing capability of the GPU chip is utilized, combined with a color high-definition LED display screen to display hitting data. The hitting data is processed in real-time, discrete flight trajectories are calculated, and the three-dimensional flight trajectory of the golf ball is simulated in animation form, without the need for external simulator software, making it more convenient to carry and use.

Abstract: A heterocyclic compound as a Janus kinase (JAK) inhibitor or a pharmaceutically acceptable salt thereof are provided, including a compound as represented by general formula (I) or a pharmaceutically acceptable salt thereof. A process for preparing the compound or a pharmaceutically acceptable salt thereof is provided. The compounds can be used for treating and/or preventing JAK-mediated related diseases, in particular inflammatory diseases, autoimmune diseases, and cancers.

Abstract: A target used for heavy water reactor production of C-14 isotopes, which comprises: a target tube, which has a target material and/or an absorber material, the target material being a nitrogen-containing solid material; end plates, which are arranged at two ends of the target tube; a connection rod, which is provided with a connection component that is connected to a positioning mechanism used for positioning the target, wherein the connection rod passes through the target tube along the axial direction of the target tube, and the target tube is fixedly connected to the connection rod by means of the end plates. The present invention can be adapted to be placed at different locations such as at a guide tube, an inspection passage, or a fuel channel to undergo irradiation and produce C-14 isotopes.

Abstract: The present invention relates to various crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide. The present invention also relates to pharmaceutical compositions comprising the crystalline forms.

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Abstract: The present invention relates to processes for preparing (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide (Compound I) in a large scale of over 1 kg. The processes provide a good yield and a purity of at least 95% of Compound I which are safe and robust.

Abstract: The present invention relates to heterocyclic compounds as immunomodulators, or pharmaceutically acceptable salts thereof. Specifically, the present invention relates to compounds as represented by general formula (I) and pharmaceutically acceptable salts thereof. The present invention also relates to methods for preparing the compounds or the pharmaceutically acceptable salts thereof. The compounds can be used for treating and/or preventing tumors, inflammations or immune diseases.

Abstract: The present invention relates to pyrimidin-4(3H)-one heterocyclic compounds for inhibiting or regulating SHP2, preparation methods thereof, and pharmaceutical use thereof. Specifically, the present invention relates to compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof, a method of applying the compounds or pharmaceutically acceptable salts thereof for treating and/or preventing SHP2-mediated diseases, particularly cancers, and preparation methods for the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to use of the compounds or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating and/or preventing SHP2-mediated diseases.

Abstract: The present invention relates to bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts thereof as inhibitors of Bruton’s tyrosine kinase (BTK) and its C481 mutant. The present invention also relates to methods for preparing Compounds A and B or their pharmaceutically acceptable salts thereof. Compounds of the present invention can be used to treat and/or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases.

Abstract: The present invention relates to heterocyclic compounds or their pharmaceutically acceptable salts thereof as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. The present invention relates to compounds shown in Formula (I) and their pharmaceutically acceptable salts thereof. The present invention also relates to methods for preparing compounds or their pharmaceutically acceptable salts thereof. Compounds of the present invention can be used to treat and/or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases.

Abstract: The present invention is directed to Compounds 1-8, and their pharmaceutically acceptable salts or prodrugs thereof. Compounds 1-8 are selective binders to TYK2's JH2 and they exhibit significant inhibitory effects on the physiological function of TYK2 and they have excellent in vivo pharmacokinetic properties. Compounds 1-5 and 7 have several deuterium substitutions on methyl to improve pharmacokinetic (PK) properties.

Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.